'en:mpccv protocol'
(id=7141293 ; fe=en:mpccv protocol ; type=1 ; niveau=200 ;
luminosité=25 ;
somme entrante=591 creation date=2017-06-25 touchdate=2025-07-15 16:43:19.000) ≈ 12 relations sortantes
- en:mpccv protocol --
r_associated #0: 30 / 1 ->
en:cisplatin/cyclophosphamide/etoposide
n1=en:mpccv protocol | n2=en:cisplatin/cyclophosphamide/etoposide | rel=r_associated | relid=0 | w=30
- en:mpccv protocol --
r_associated #0: 30 / 1 ->
en:cyclophosphamide
n1=en:mpccv protocol | n2=en:cyclophosphamide | rel=r_associated | relid=0 | w=30
- en:mpccv protocol --
r_associated #0: 29 / 0.967 ->
en:prednisone
n1=en:mpccv protocol | n2=en:prednisone | rel=r_associated | relid=0 | w=29
- en:mpccv protocol --
r_associated #0: 28 / 0.933 ->
en:semustine
n1=en:mpccv protocol | n2=en:semustine | rel=r_associated | relid=0 | w=28
- en:mpccv protocol --
r_associated #0: 27 / 0.9 ->
en:melphalan
n1=en:mpccv protocol | n2=en:melphalan | rel=r_associated | relid=0 | w=27
- en:mpccv protocol --
r_associated #0: 26 / 0.867 ->
en:antineoplastic combined chemotherapy protocols
n1=en:mpccv protocol | n2=en:antineoplastic combined chemotherapy protocols | rel=r_associated | relid=0 | w=26
- en:mpccv protocol --
r_associated #0: 26 / 0.867 ->
en:vincristine
n1=en:mpccv protocol | n2=en:vincristine | rel=r_associated | relid=0 | w=26
- en:mpccv protocol --
r_associated #0: 20 / 0.667 ->
cyclophosphamide
n1=en:mpccv protocol | n2=cyclophosphamide | rel=r_associated | relid=0 | w=20
- en:mpccv protocol --
r_associated #0: 20 / 0.667 ->
en:melphalanum
n1=en:mpccv protocol | n2=en:melphalanum | rel=r_associated | relid=0 | w=20
- en:mpccv protocol --
r_associated #0: 20 / 0.667 ->
en:sarcolysin
n1=en:mpccv protocol | n2=en:sarcolysin | rel=r_associated | relid=0 | w=20
- en:mpccv protocol --
r_associated #0: 20 / 0.667 ->
melphalan
n1=en:mpccv protocol | n2=melphalan | rel=r_associated | relid=0 | w=20
- en:mpccv protocol --
r_associated #0: 2 / 0.067 ->
en:therapeutic or preventive procedure
n1=en:mpccv protocol | n2=en:therapeutic or preventive procedure | rel=r_associated | relid=0 | w=2
| ≈ 21 relations entrantes
- melphalan ---
r_associated #0: 101 -->
en:mpccv protocol
n1=melphalan | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=101
- en:melphalan ---
r_associated #0: 100 -->
en:mpccv protocol
n1=en:melphalan | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=100
- en:sarcolysin ---
r_associated #0: 100 -->
en:mpccv protocol
n1=en:sarcolysin | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=100
- en:melphalanum ---
r_associated #0: 36 -->
en:mpccv protocol
n1=en:melphalanum | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=36
- cyclophosphamide ---
r_associated #0: 31 -->
en:mpccv protocol
n1=cyclophosphamide | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=31
- en:cyclophosphamide ---
r_associated #0: 31 -->
en:mpccv protocol
n1=en:cyclophosphamide | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=31
- en:antineoplastic combined chemotherapy protocols ---
r_associated #0: 20 -->
en:mpccv protocol
n1=en:antineoplastic combined chemotherapy protocols | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=20
- en:cisplatin/cyclophosphamide/etoposide ---
r_associated #0: 20 -->
en:mpccv protocol
n1=en:cisplatin/cyclophosphamide/etoposide | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=20
- en:prednisone ---
r_associated #0: 20 -->
en:mpccv protocol
n1=en:prednisone | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=20
- en:semustine ---
r_associated #0: 20 -->
en:mpccv protocol
n1=en:semustine | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=20
- en:vincristine ---
r_associated #0: 20 -->
en:mpccv protocol
n1=en:vincristine | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=20
- cyclope (oeil) ---
r_associated #0: 15 -->
en:mpccv protocol
n1=cyclope (oeil) | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=15
- Cyclophosphamide ---
r_associated #0: 10 -->
en:mpccv protocol
n1=Cyclophosphamide | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=10
- Melphalan ---
r_associated #0: 10 -->
en:mpccv protocol
n1=Melphalan | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=10
- en:cyclops eye ---
r_associated #0: 10 -->
en:mpccv protocol
n1=en:cyclops eye | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=10
- prednisone ---
r_associated #0: 10 -->
en:mpccv protocol
n1=prednisone | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=10
- sémustine ---
r_associated #0: 10 -->
en:mpccv protocol
n1=sémustine | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=10
- vincristine ---
r_associated #0: 10 -->
en:mpccv protocol
n1=vincristine | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=10
- cyclopeptide ---
r_associated #0: 5 -->
en:mpccv protocol
n1=cyclopeptide | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=5
- cyclophiline ---
r_associated #0: 5 -->
en:mpccv protocol
n1=cyclophiline | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=5
- cyclophorie ---
r_associated #0: 5 -->
en:mpccv protocol
n1=cyclophorie | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=5
|